Livzon Pharmaceutical Group Inc (SHE:000513) — Market Cap & Net Worth
Market Cap & Net Worth: Livzon Pharmaceutical Group Inc (000513)
Livzon Pharmaceutical Group Inc (SHE:000513) has a market capitalization of $2.29 Billion (CN¥15.63 Billion) as of September 16, 2026. Listed on the SHE stock exchange, this China-based company holds position #5702 globally and #1048 in its home market, demonstrating a -2.14% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Livzon Pharmaceutical Group Inc's stock price CN¥26.58 by its total outstanding shares 588100054 (588.10 Million). Also see Livzon Pharmaceutical Group Inc asset portfolio for a full breakdown of the balance sheet.
Livzon Pharmaceutical Group Inc Market Cap History: 2015 to 2026
Livzon Pharmaceutical Group Inc's market capitalization history from 2015 to 2026. Data shows growth from $1.74 Billion to $2.29 Billion (3.24% CAGR). Also see 000513 operating cash flow for how efficiently the company converts equity into cash flow.
Livzon Pharmaceutical Group Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Livzon Pharmaceutical Group Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Livzon Pharmaceutical Group Inc share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.25x
Livzon Pharmaceutical Group Inc's market cap is 0.25 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.47x
Livzon Pharmaceutical Group Inc's market cap is 1.47 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.82 Billion | $7.65 Billion | $784.35 Million | 0.24x | 2.32x |
| 2017 | $2.66 Billion | $8.53 Billion | $4.43 Billion | 0.31x | 0.60x |
| 2018 | $1.35 Billion | $8.86 Billion | $1.08 Billion | 0.15x | 1.25x |
| 2019 | $2.44 Billion | $9.38 Billion | $1.30 Billion | 0.26x | 1.87x |
| 2020 | $3.02 Billion | $10.52 Billion | $1.71 Billion | 0.29x | 1.76x |
| 2021 | $3.07 Billion | $12.06 Billion | $1.78 Billion | 0.25x | 1.73x |
| 2022 | $2.58 Billion | $12.63 Billion | $1.91 Billion | 0.20x | 1.35x |
| 2023 | $2.90 Billion | $12.43 Billion | $1.95 Billion | 0.23x | 1.49x |
| 2024 | $3.27 Billion | $11.81 Billion | $2.06 Billion | 0.28x | 1.59x |
| 2025 | $2.97 Billion | $11.91 Billion | $2.02 Billion | 0.25x | 1.47x |
Competitor Companies of 000513 by Market Capitalization
Companies near Livzon Pharmaceutical Group Inc in the global market cap rankings as of September 16, 2026. Review Livzon Pharmaceutical Group Inc (000513) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Livzon Pharmaceutical Group Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Livzon Pharmaceutical Group Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Livzon Pharmaceutical Group Inc's market cap moved from $1.74 Billion to $ 2.29 Billion, with a yearly change of 3.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.29 Billion | -22.87% |
| 2025 | CN¥2.97 Billion | -9.32% |
| 2024 | CN¥3.27 Billion | +12.58% |
| 2023 | CN¥2.90 Billion | +12.38% |
| 2022 | CN¥2.58 Billion | -15.89% |
| 2021 | CN¥3.07 Billion | +1.84% |
| 2020 | CN¥3.02 Billion | +23.71% |
| 2019 | CN¥2.44 Billion | +80.45% |
| 2018 | CN¥1.35 Billion | -49.24% |
| 2017 | CN¥2.66 Billion | +46.28% |
| 2016 | CN¥1.82 Billion | +4.84% |
| 2015 | CN¥1.74 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Livzon Pharmaceutical Group Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.29 Billion USD |
| MoneyControl | $2.29 Billion USD |
| MarketWatch | $2.29 Billion USD |
| marketcap.company | $2.29 Billion USD |
| Reuters | $2.29 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Livzon Pharmaceutical Group Inc
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, il… Read more